

Editorial

Dihydropyrimidine Dehydrogenase Activity: Prognostic Partner of 5-Fluorouracil?

Carmen J. Allegra¹

Medicine Branch, National Cancer Institute, Bethesda, Maryland
20892-1906

5-FU² is one of the most commonly prescribed anticancer agents having notable activity in the treatment of cancers arising from the breast, gastrointestinal tract, and head and neck. The metabolism, mechanisms of action and resistance, and pharmacokinetics of 5-FU have been extensively investigated since its synthesis over 4 decades ago. Despite a longstanding knowledge of the metabolic pathways governing the fate of 5-FU, it is only recently that cellular activities of particular metabolic steps critical in the metabolism of 5-FU have been used as a potential means for defining populations of patients at increased risk for the toxic side effects of the drug, as well as those who may derive the greatest clinical benefit from its use. DPD is the critical rate-limiting step in the catabolism of 5-FU and accounts for 80–90% of the drug's clearance. Thus, the level of this enzyme may be an important determinant in predicting toxicity associated with the use of 5-FU and potentially for predicting patients whose tumors are most likely to respond to treatment with 5-FU. In this issue of *Clinical Cancer Research*, Johnson *et al.* (1) describe severe multiorgan toxicity associated with the topical application of 5% 5-FU cream to the scalp of a 76-year-old male patient with basal cell carcinoma (1). This unusual and heretofore unreported example of severe toxicity associated with the topical use of 5-FU was shown by the authors to be the result of virtually undetectable DPD enzymatic activity in the PBMCs of the patient. Given the generally accepted safety of topical 5-FU use, this case represents a striking example of the severity of toxicities that may be associated with even minor exposure to 5-FU in patients with severe DPD deficiency. It has been estimated that ~3–5% of patients have PBMC DPD activity less than the 95% of the lower limit for the normal population (150 pmol/min/mg protein) and are considered to be at a high risk for the development of severe or life-threatening toxicities with the use of 5-FU (2–5). The risk of lethal toxicities is even greater for those patients with DPD activity \leq 100 pmol/min/mg protein (\leq 99% of normal population).

Tuchman *et al.* (6) were the first to describe severe toxicity, including semi-coma associated with the use of 5-FU in a 27-year old woman undergoing adjuvant therapy for the treatment of breast cancer. Although these investigators did not directly measure DPD activity, the association of pyrimidinemia

and pyrimidinuria in the patient, as well as in a sibling, suggested that the toxicity associated with 5-FU was the result of a genetic defect in the degradation of uracil and thymidine, most likely due to a deficiency of DPD. Subsequent investigations by *Diasio et al.* (7), in a second reported case of severe toxicity associated with the use of 5-FU, identified a complete lack of DPD enzymatic activity (7). Additional investigations in family members suggested an autosomal recessive pattern of inheritance. Although patients with severe or complete DPD deficiency have a high incidence of toxicity associated with the use of 5-FU, there does not seem to be a significant correlation between DPD levels within the normal range and 5-FU-associated toxicity (8). Thus, the potential role for DPD quantitation in normal tissues (PBMCs) may be limited to the identification of patients with DPD levels 2 or 3 SDs lower than the population mean and are, thus, at the highest risk for toxicity, particularly neurotoxicity, associated with the use of 5-FU. It is important to note that although the greatest site for 5-FU catabolism is in the liver, the PBMC DPD levels have been shown to closely correlate with DPD activity in normal liver, thus supporting the use of PBMCs as surrogate for total body DPD activity (9). However, recent investigations have identified monocytes as containing 3-fold more DPD activity than lymphocytes, thus the relative ratios of various mononuclear cell fractions needs to be accounted for particularly in those patients whose levels of DPD approach the 95th percentile (10). For those patients who develop severe neurological toxicity associated with the use of 5-FU in the setting of DPD deficiency, infusional thymidine may be considered a potential rescue agent. A report by Takimoto and colleagues demonstrated the value of such an approach in a patient who developed severe encephalopathy associated with the use of 5-FU and who was subsequently found to be severely DPD deficient (11).

In addition to its role as a predictor of toxicity associated with 5-FU use, DPD levels may also aid in the prognostication of patient populations whose tumors are likely to respond to 5-FU. Low levels of DPD activity in normal tissues may predict for a greater fluorouracil exposure and, thus, the possibility of enhanced tumor response. Perhaps more critical are intratumoral levels of DPD that regulate intracellular 5-FU levels and, thus, may be an important determinant of clinical outcome. Preclinical work using cancer cell lines found DPD levels to be, at best, only poorly correlated with 5-FU responsiveness (12, 13). Nonetheless, several groups have investigated the predictive value of DPD as an indicator of sensitivity to 5-FU in patients. These results, albeit in relative small numbers of patients, suggest that low levels of intratumoral DPD expression are associated with 5-FU responsiveness (14–16). Given the ease with which PBMCs may be obtained, it has been suggested that this tissue may serve as a surrogate for DPD activity in tumor tissue. However, a recent investigation of colorectal tumors taken from 57 patients found only a poor correlation of DPD levels in tumor tissue with that in the PBMCs, thus supporting the need for

Received 4/29/99; accepted 5/7/99.

¹ To whom requests for reprints should be addressed, at Medicine Branch, National Cancer Institute, Building 10, Room 12N226, 10 Center Drive, MSC 1906, Bethesda, MD 20892-1906.

² The abbreviations used are: 5-FU, 5-fluorouracil; DPD, dihydropyrimidine dehydrogenase; PBMC, peripheral blood mononuclear cell.

tumor tissue measurements of DPD in the assessment of DPD as a potential predictor of 5-FU responsiveness (17). Clearly, the value of DPD as a predictor of 5-FU responsiveness will need to be explored in larger numbers of patients in a prospective fashion before definitive conclusions may be reached regarding its use.

In the present study, the authors identified the molecular defect responsible for the complete lack of DPD enzymatic activity, namely, a G to A mutation in a 5' splicing recognition sequence, which results in deletion of all 165 bp of exon 14. This particular mutation, as well as a variety of other point mutations and deletions of the *DPD* gene, were identified previously (18–22). Perhaps the most complete cataloging of mutations that result in complete deficiency of DPD has been undertaken by Van Kuilenburg *et al.* (18), wherein 17 families representing 22 patients with complete deficiency of DPD were studied (18). Although seven different mutations were identified, more than half of the patients demonstrated the identical G to A point mutation described in the present study, suggesting that this is probably the most common mutation identified to date that is associated with complete absence of DPD activity. Despite the presence of various clinical abnormalities in the patients with absence of DPD activity, no definitive genotype-phenotype associations have been identified.

Ubiquitination is becoming recognized as a common mechanism regulating a host of cellular processes with well over 50 ubiquitination substrates having been identified. In general, ubiquitination targets proteins to the 26S proteasome wherein the polyubiquitinated proteins are degraded. It has been shown that not all ubiquitinated proteins are targeted for degradation, and it has been postulated that this posttranslational modification may have other critical cellular functions. It is interesting that the authors of the present study describe ubiquitination of the mutant DPD protein. Several possible explanations exist for this observation. The ubiquitination process may be part of the normal cellular physiology that regulates the level of DPD. Implicit is the notion that dysregulation of this process may represent a means for overexpression and, therefore, tumor resistance to 5-FU. If ubiquitination was part of normal cellular physiology, one would need to postulate why ubiquitin is observed on the mutant DPD protein, but not wild type. The process of ubiquitination has also been described as a cellular mechanism designed to scavenge and degrade mutant or misfolded proteins (23, 24). This latter possibility represents an alternative explanation that would also account for the lack of observed ubiquitination of the wild-type enzyme, but may not constitute a mechanism for regulating enzyme activity, assuming the mutant forms are already catalytically inactive. Whether ubiquitination of DPD is part of the normal cellular physiology or represents the cells attempt to simply rid itself of aberrant molecules will await further investigations. In either case, the role of ubiquitination as a regulator of DPD represents an important area for future investigations given the relative importance of DPD as a potential predictor of both response and toxicity associated with the use of 5-FU.

Given the potential value of DPD as a determinant of both tumor responsiveness and toxicity associated with 5-FU, recent attempts have focussed on modulating the activity of 5-FU through the inhibition of DPD. Several agents are undergoing

clinical testing and include UFT, which contains the 5-FU prodrug ftorafur in a 1:4 molar ratio with uracil, a competitive inhibitor of DPD; eniluracil (ethynyluracil, GW776C85), a direct inhibitor of DPD; and S-1, which contains a direct inhibitor of DPD (5-chloro-2,4-dihydropyridine). The hope is that these agents will prolong the intracellular half-life of 5-FU through inhibition of intratumoral DPD, but these compounds also inhibit DPD found in the normal tissues responsible for clearance of the drug, thus markedly prolonging the total body exposure to 5-FU with associated increased toxicity. A critical issue will be whether the use of these inhibitors can enhance the therapeutic index of 5-FU through relatively selective tumor *versus* normal tissue DPD inhibition. However, even in the absence of a selective advantage, the use of DPD inhibitors has provided a means for developing oral 5-FU-based regimens, an important advance in convenience and quality of life for patients requiring 5-FU therapy. One caveat is that other agents used for noncancer indications, such as the antiviral sorivudine, can have important drug-drug interactions through the inhibition of DPD. This particular antiviral agent led to the death of 16 patients in Japan who were being treated with the antiviral medication while undergoing therapy with 5-FU (25).

The report by Johnson *et al.* (1) illustrates the critical role of DPD in governing 5-FU-associated toxicity in patients with severe enzyme deficiency. The role of DPD as a predictor of toxicity for patients with levels within the normal range and as a predictor of tumor response awaits further clinical investigations. The prediction of tumor response based on the make-up of molecular response determinants in a given individual's tumor is a critically important area for future investigation and holds enormous promise for advancing the field of cancer therapeutics.

REFERENCES

1. Johnson, M. R., Hageboutros, A., Wang, K., High, L., Smith, J. B., and Diasio, R. B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient following treatment with topical 5-fluorouracil. *Clin. Cancer Res.*, 5: 2006–2011, 1999.
2. Diasio, R. B., and Lu, Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. *J. Clin. Oncol.*, 12: 2239–2242, 1994.
3. Lu, Z., Zhang, R., Carpenter, J. T., and Diasio, R. B. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. *Clin. Cancer Res.*, 4: 326–329, 1998.
4. Milano, G., Etienne, M. C., Pierrefite, V., Barberi-Heyob, M., Deporte-Fety, R., and Renée, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. *Br. J. Cancer*, 79: 627–630, 1999.
5. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. *Cancer Res.*, 53: 5433–5438, 1993.
6. Tuchman, M., Stoeckeler, J. S., Kiang, D. T., O'Dea, R. F., Ramnaraine, M. L., and Mirkin, B. L. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. *N. Engl. J. Med.*, 313: 245–249, 1985.
7. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. *J. Clin. Invest.*, 81: 47–51, 1988.
8. Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thys, A., Renée, N., Schneider, M., Demard, F., and Milano, G. Population

- study of dihydropyrimidine dehydrogenase in cancer patients. *J. Clin. Oncol.*, *12*: 2248–2253, 1994.
9. Chazal, M., Etienne, M. C., Renée, N., Bourgeon, A., Richelme, H., and Milano, G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. *Clin. Cancer Res.*, *5*: 507–510, 1996.
10. Van Kuilenburg, A. B. P., Van Lenthe, H., Blom, M. J., Mul, E. P. J., and Van Gennip, A. H. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. *Br. J. Cancer*, *79*: 620–626, 1999.
11. Takimoto, C. H., Lu, Z-H., Zhang, R., Liang, M. D., Larson, L. V., Cantilena, L. R., Grem, J. L., Allegra, C. J., Diasio, R. B., and Chu, E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. *Clin. Cancer Res.*, *2*: 477–481, 1996.
12. Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. *Eur. J. Cancer*, *30A*: 1517–1522, 1994.
13. Grem, J., Danenberg, K., Behan, K., Parr, A., Young, L., Nguyen, D., Danenberg, P., Drake, J., Monks, A., and Allegra, C. Thymidine kinase, thymidylate synthase, dihydropyrimidine dehydrogenase and p53 profiles of cell lines in the National Cancer Institute anticancer drug screen. *Proc. Am. Assoc. Cancer Res.*, *40*: 8, 1999.
14. Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Dasonville, O., Renée, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. *J. Clin. Oncol.*, *13*: 1663–1670, 1995.
15. Diasio, R. B., Danenberg, K., Johnson, M., and Danenberg, P. Quantitation of dihydropyrimidine dehydrogenase expression in tumor specimens of patients treated with 5-fluorouracil using a quantitative polymerase chain reaction assay. *Proc. Am. Assoc. Cancer Res.*, *39*: 188, 1998.
16. Terashima, M., Nakaya, T., Irinoda, T., Takiyama, I., Sasaki, N., Takagane, A., Abe, K., Araya, M., Nishizuka, S., Shimooki, O., Yonezawa, H., Oyama, K., Kawamura, H., and Saito, K. Analysis of thymidylate synthase, dihydropyrimidine dehydrogenase and 5-FU sensitivity in gastric cancer. *Proc. Am. Assoc. Cancer Res.*, *39*: 607, 1998.
17. McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A., Park, K., Koruth, M., and Cassidy, J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. *Br. J. Cancer*, *77*: 461–465, 1998.
18. Van Kuilenburg, A. B. P., Vreken, P., Abeling, N. G. G. M., Bakker, H. D., Meinsma, R., Van Lenthe, H., De Abreu, R. A., Smeitink, J. A. M., Kayserili, H., Apak, M. Y., Christensen, E., Holopainen, I., Pulkki, K., Riva, D., Botteon, G., Holme, E., Tulinius, M., Kleijer, W. J., Beemer, F. A., Duran, M., Niezen-Koning, K. E., Smit, G. P. A., Jakobs, C., Smit, L. M. E., Moog, U., Spaapen, L. J. M., and Van Gennip, A. H. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. *Hum. Genet.*, *104*: 1–9, 1999.
19. Wei, X., McLeod, H. L., McMurrrough, J., Gonzalez, F. J., and Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. *J. Clin. Invest.*, *98*: 610–615, 1996.
20. Ridge, S. A., Sludden, J., Brown, O., Roberttson, L., Wei, X., Sapone, A., Fernandez-Salguero, P. M., Gonzalez, F. J., Vreken, P., Van Kuilenburg, A. B. P., Van Gennip, A. H., and McLeon, H. L. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. *Br. J. Clin. Pharmacol.*, *46*: 151–156, 1998.
21. Kouwaki, M., Hamajima, N., Sumi, S., Nonaka, M., Sasaki, M., Dobashi, K., Kidouchi, K., Togari, H., and Wada, Y. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. *Clin. Cancer Res.*, *4*: 2999–3004, 1998.
22. Meinsma, R., Fernandez-Salguero, P., Van Kuilenburg, A. B., Van Gennip, A. H., and Gonzalez, F. J. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria. *DNA Cell Biol.*, *14*: 1–6, 1995.
23. Weissman, A. M. Regulating protein degradation by ubiquitination. *Immunol. Today*, *18*: 1023–1032, 1997.
24. Bonifacino, J. S., and Weissman, A. M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. *Annu. Rev. Cell Dev. Biol.*, *14*: 19–57, 1998.
25. Diasio, R. B. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. *Br. J. Clin. Pharmacol.*, *46*: 1–4, 1998.

Clinical Cancer Research

Dihydropyrimidine Dehydrogenase Activity: Prognostic Partner of 5-Fluorouracil?

Carmen J. Allegra

Clin Cancer Res 1999;5:1947-1949.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/5/8/1947>

Cited articles This article cites 23 articles, 8 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/5/8/1947.full#ref-list-1>

Citing articles This article has been cited by 3 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/5/8/1947.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/5/8/1947>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.